NIH, pharma and nonprofits form $230M partnership to validate disease targets
The National Institutes of Health (NIH) has joined 10 biopharmaceutical companies and several nonprofit organizations in the Accelerating Medicines Partnership (AMP), designed to improve identification and validation of biomarkers for drug development.
In the first round of projects, AMP partners will invest more than $230 million over five years in the study of Alzheimer’s disease, type 2 diabetes, rheumatoid arthritis and lupus.
AMP partners have agreed to make data and analyses generated by the projects publicly available to the broader biomedical community.
In addition to the NIH, the FDA also will be a government partner in the project. The 10 industry partners are:
- AbbVie
- Biogen Idec
- Bristol-Myers Squibb
- GlaxoSmithKline
- Johnson & Johnson
- Lilly
- Merck
- Pfizer
- Sanofi
- Takeda
AMP’s nonprofit partners are:
- Alzheimer’s Association
- American Diabetes Association
- Lupus Foundation of America
- Foundation for the NIH
- Geoffrey Beene Foundation
- PhRMA
- Rheumatology Research Foundation
- USAgainstAlzheimer’s
For more information about AMP, click here.
Evan joined TriMed in 2011, writing primarily for Health Imaging. Prior to diving into medical journalism, Evan worked for the Nine Network of Public Media in St. Louis. He also has worked in public relations and education. Evan studied journalism at the University of Missouri, with an emphasis on broadcast media.